# RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

> **NCT04597125** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Bayer** · enrollment: 654 (actual)

## Conditions studied

- Metastatic Castrate Resistant Prostate Cancer (mCRPC)

## Interventions

- **DRUG:** Radium-223 dichloride (Xofigo, BAY88-8223)
- **DRUG:** ARPI therapy

## Key facts

- **NCT ID:** NCT04597125
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-11-09
- **Primary completion:** 2025-11-21
- **Final completion:** 2026-10-12
- **Target enrollment:** 654 (ACTUAL)
- **Last updated:** 2026-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04597125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04597125, "RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT04597125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*